help your patients understand their risk of a severe immune response to COVID-19.

EpiSwitch CST is the first and only commercially-available blood test for the prediction of COVID-19 severity in ANY adult, independent of COVID-19 status. The test can help patients understand - and cope - with their individual level of risk.

EpiSwitch CST is designed to provide healthcare professionals (HCPs) and their adult patients with actionable, decision-making information regarding infection mitigation during the COVID-19 pandemic based on the unique 3D genetic immune profile of each individual.

The test is variant-agnostic so it identifies risk due to regular SARS-CoV-2, as well as delta, omicron, and other strains.

The EpiSwitch CST report includes clear guidance for HCPs to interpret an adult patient’s risk score and formulate an effective management plan.

Individuals with a high-risk EpiSwitch CST score are at increased probability of experiencing a severe immune response to COVID-19. Such individuals should be counseled on their risk level and may benefit from a mitigation-strategy review to avoid infection. In the event of infection, early use of medications or other interventions are recommended.

Those at average risk should not be construed as having no risk; complications that do not require critical care are possible.

Risk results do not provide information about an individual’s risk of becoming infected. Regardless of risk results, government and local health-department guidelines must be followed to avoid transmitting the virus.